Secretory breast cancer in a 7.5-year old boy

Szántó, J.; András, C.; Tsakiris, J.; Gomba, S; Szentirmay, Zoltán; Bánlaki, S.; István, Szilágyi; Kiss, Csongor; Antall, P.; Horváth, Alpár; Lengyel, L.; Castiglione‐Gertsch, Monica

doi:10.1016/j.breast.2004.02.011

Cited by 37 publications

(33 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sentinel lymph node biopsy has been used in several studies and has proven to be a useful evaluation method for the lymph node status of secretory breast carcinoma. 6,20,22 Three patients in our series received a sentinel lymph node biopsy, and one of these cases showed a positive result. However, considering that the patient was very young, lumpectomy without axillary dissection was adopted.…”

Section: Discussionmentioning

confidence: 80%

“…The reported incidence rate of axillary lymph node metastasis of secretory breast carcinoma is 15-30%, 6,17 and most patients involved no more than four lymph nodes. [18][19][20][21][22][23] Studies have shown that lymph node metastasis is rare in children and teenagers.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 27 cases (including 2 cases from our study, see Table 3) of male patients with secretory breast carcinoma could be identified in the literature. 2,3,6,9,23,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] Most affected patients were children and adolescents with a median age of 27 years. The tumors are usually located subareolarly.…”

Section: Discussionmentioning

confidence: 99%

“…3,4 Immunochemically, the tumor usually has shown strong reactivity for S-100 and is negative for estrogen receptor (ER), progesterone receptor (PR) and HER2. [4][5][6][7] In 2002, Tognon et al 8 were the first to report that secretory breast carcinoma expresses the ETV6-NTRK3 gene fusion in 12 out of 13 of their cases. Recently, Laé et al 7 demonstrated that secretory breast carcinoma with the ETV6-NTRK3 fusion gene belongs to the phenotypic spectrum of basal-like breast carcinomas, and immunohistochemical, as well as genetic features of secretory breast carcinomas, distinguished them from other basal-like breast cancers.…”

Section: Secretory Breast Carcinoma Was Originally Recognized In 1966mentioning

confidence: 99%

See 3 more Smart Citations

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

et al. 2012

View full text Add to dashboard Cite

Secretory breast carcinoma is a rare breast cancer with indolent clinical behavior. Recent research showed that secretory breast carcinoma belongs to the phenotypic spectrum of basal-like breast carcinomas. In this study, a clinicopathological and immunophenotypic analysis of secretory breast carcinomas from 15 Chinese patients was conducted. This patient group consisted of 2 males and 13 females, with ages ranging from 10 to 67 years old (median, 36 years old). All patients presented with a painless and firm mass. Tumor size ranged from 10 to 55 mm. Most tumors were located in the outer upper quadrant of the breast. Two patients (2 of 13, 15%) displayed positive axillary lymph nodes. At the microscopic level, the presence of intracellular and extracellular secretory material was the most remarkable feature. Most cases showed mild dysplasia cytologically. All cases were negative for estrogen receptor, progesterone receptor and HER2. The expression rate of the basal-like marker (CK5/6 or epidermal growth factor receptor) was 87% (13 of 15). The basal-like phenotype was identified in 13 cases (87%). Follow-up time ranged from 10 to 55 months (median, 19 months). None of the cases had evidence of recurrence and metastasis. Our study reveals that secretory breast carcinoma is a distinct subset of invasive breast carcinoma, with expression of basal-like markers. It should be noted that secretory breast carcinoma is different from conventional basal-like breast carcinomas. Future studies are required to further understand the prognostic significance of the basal-like markers expression in secretory breast carcinomas.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Secretory Breast Carcinoma Was Originally Recognized In 1966mentioning

confidence: 99%

See 2 more Smart Citations

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

et al. 2012

View full text Add to dashboard Cite

show abstract

“…These neoplasms can have late local recurrences but is generally associated with prolonged survival, even with axillary lymphnode involvement [3,4]. Immunochemically, the tumor usually shows strong reactivity for S-100 but is negative for estrogen receptor (ER), progesterone receptor (PR) and HER2 neu protein [5][6][7]. In 2002, Tognon et al [8] reported that secretory breast carcinoma expressed the ETV6-NTRK3 gene fusion in 12 out of 13 of their cases, which is now considered to be a differentiating factor from other basal-like breast cancers.…”

Section: Discussionmentioning

confidence: 99%

Secretory Carcinoma of Breast in a Patient Treated for Differentiated Thyroid Carcinoma—A Diagnostic Dilemma

Ganesh

Muralee

Saxena

et al. 2014

Indian J Surg Oncol

View full text Add to dashboard Cite

Secretory carcinoma of the breast is a rare entity accounting for less than 1 % of all infiltrating breast carcinomas. Though initially considered as "juvenile breast carcinoma", due to its occurrence predominantly in pediatric population, it was later found to present in other age groups as well. We report a case of secretory carcinoma breast in a middle aged woman who had undergone treatment for papillary carcinoma of thyroid previously. The uniqueness of this malignancy and the diagnostic dilemma due to patient's past medical history, are discussed in detail.

show abstract

Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients

Kayton

Delgado

Busam

et al. 2008

Cancer

View full text Add to dashboard Cite

BACKGROUND Few data exist regarding techniques, indications, and outcomes for sentinel lymph node biopsy in pediatric patients with sarcomas and carcinomas. METHODS A retrospective 10‐year review was conducted, with Institutional Review Board waiver, of the pathology, lymphoscintigraphy, and clinical records for all pediatric patients selected to undergo sentinel lymph node biopsy at a major cancer center. RESULTS Thirty‐one sentinel lymph node biopsies were performed in 30 pediatric patients (median age, 12 years; range, 2–21 years). With the administration of technetium 99m sulfur colloid, sentinel lymph nodes were identified preoperatively in 30 of 31 cases, and intraoperatively in the remaining case. Radiotracer alone was used in 13 of 31 cases but was supplemented with isosulfan blue dye in the remaining 18 cases. There were no complications. Positive sentinel lymph nodes occurred in 1 of 9 patients with rhabdomyosarcoma and in 2 of 5 patients with breast cancer, and in both of these diseases the sentinel lymph node results helped guide treatment decisions. No other patients had positive sentinel lymph nodes, and among those with nonrhabdomyosarcoma soft‐tissue sarcomas there were no lymph node basin recurrences despite a lack of lymph node basin irradiation or formal lymph node dissection. The median follow‐up was 48 months (range, 0‐111 months). CONCLUSIONS Sentinel lymph node biopsy for pediatric soft‐tissue tumors can be performed safely, and the results can alter treatment decisions both for children with rhabdomyosarcoma and adolescents with breast cancer. In patients with nonrhabdomyosarcoma soft‐tissue sarcoma, we observed no positive sentinel lymph nodes and no lymph node basin recurrences; these data should prompt the prospective study of sentinel lymph node biopsy as a modality that might help guide the administration or withholding of regional therapy among pediatric patients with nonrhabdomyosarcoma soft‐tissue sarcoma. Cancer 2008. © 2008 American Cancer Society.

show abstract

Secretory breast cancer in a 7.5-year old boy

Cited by 37 publications

References 6 publications

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

Secretory Carcinoma of Breast in a Patient Treated for Differentiated Thyroid Carcinoma—A Diagnostic Dilemma

Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients

Contact Info

Product

Resources

About